Top Healthcare Stocks
Healthcare stocks were lower this afternoon with the NYSE
Healthcare Sector Index declining around 0.9% and shares of
healthcare companies in the S&P 500 also were down 0.9% as a
In company news, Oxford Immunotec Global (
) was weaker today after the company reported mixed financial
results for Q2 ended June 30, 2014, and said it sees Q3 revenue
below Street estimates and fiscal 2014 revenue in line.
Shares were down nearly 11% at $15.15 apiece, earlier falling to
a session low of $15.00 a share.
The commercial-stage diagnostics company posted Q2 net loss of
$6.2 million or $0.36 per share, compared with the prior-year
period's $1.0 million or $0.42 per share. Revenue was $11.8
million, up 16% from $10.2 million in the same quarter last
Analysts polled by Capital IQ were expecting a loss of $0.20 per
share on revenues of $11.38 million.
For Q3, the company expects revenue of $12.4 million - $12.9
million, versus the Street view of $13.36 million. It also
anticipates fiscal 2014 revenue of $48 million - $50 million,
versus the analysts' estimate of $49.91 million.
In other sector news,
(+) ISR, Reports first major peer-reviewed study of 24 patents
with metastitic brain cancer implanted with strands of its
Cesium-131 seeds had superior results, fewer complications and
improved quality of life compared to other radiation therapies.
(-) RIGL, Q2 net loss of $0.29 per share was $0.06 wider than
the Capital IQ consensus. There was no contract revenue from
collaborations during the quarter, down from $1.4 mln last
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.